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Study Type – Symptom prevalence study 
(prospective cohort) 




To describe the design and baseline cohort 
characteristics of the Benign Prostatic 
Hyperplasia (BPH) Registry and Patient Survey, 
an ongoing, prospective, observational, 
disease registry documenting management 
practices and patient outcomes in men in the 
USA with lower urinary tract symptoms 





Men with LUTS/BPH who were either 












(5ARIs), a combination of these medications, 
or anticholinergics, and who met selection 
criteria, were enrolled at sites throughout the 
USA. At each visit, standardized forms and 
validated questionnaires were completed to 
assess the physicians’ management practices 
and patients’ clinical characteristics, sexual 




At the close of recruitment (February 2005), 
6909 men (mean age 66.0 years) were 
enrolled at 402 sites by urologists and 
primary-care physicians. Before enrolment, 
49% of the men were managed with watchful 
waiting (WW), 21% with uroselective AB 
monotherapy, 11% with non-uroselective AB 
monotherapy, 6% with 5ARI monotherapy, 




 5ARI, and 2% with 
anticholinergics. After enrolment, 42% were 
on WW and 26% were on selective AB 
monotherapy; changes in other management 
groups were minimal. Overall, 33% of the men 
had mild, 52% had moderate and 15% had 
severe LUTS. The most common comorbidities 
were hypertension (53%), high cholesterol 




The BPH Registry and Patient Survey 
will provide information on physician 
management practices and outcomes of 
 
The first paper describes the design
and baseline characteristics of
patients in the BPH Registry and
Patient Survey in the USA. This
important study will provide
information on management
practices and outcomes of men
with this condition, as well as




Another important study in the
USA is the Boston Area Community
Health Survey, and in this issue the
authors estimate the future
magnitude of urological symptoms
in that country. They found that it
might reach the current level of
cardiovascular disease and
suggested that this will have huge
affects on health service policy.
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men with LUTS/BPH, while examining the 
effects of demographics, socio-economics, 




prostatic hyperplasia, lower urinary tract 
symptoms, registries, outcome assessment, 
 




BPH is a common cause of morbidity in 
ageing men; depending on the degree of 
bother, men with BPH might complain of 
one or more LUTS, including increased 
frequency of urination, nocturia, hesitancy, 
urgency, straining, intermittency, dribbling, 
incomplete bladder emptying, and a weak 
urinary stream. The prevalence of histological 
BPH is 50% in men aged 51–60 years and 
increases to 90% in those aged 81–90 years 
[1]. BPH can be a progressive disease that 
might cause serious complications, including 
haematuria, recurrent UTIs, acute urinary 
retention and, rarely, renal insufficiency 
[2,3]. LUTS are also associated with sexual 
dysfunction, bother, worry and interference 
with daily activities. The results of population-
based epidemiological studies show that 
LUTS are an independent risk factor for 
both erectile dysfunction (ED) and 
ejaculatory dysfunction [4,5]. Furthermore, 
men with moderate-to-severe LUTS report 
significant decreases in health-related quality 
of life, with 4–6 times the bother and 
interference with daily activities and twice 
the worry of men with mild LUTS [6]. 
Increased bother/decreased quality of life 
is the main reason that men seek help for 
LUTS associated with BPH (LUTS/BPH) and 
is a primary consideration in the treatment 
recommendations of the AUA BPH guideline 
[7]. Despite increased knowledge of the 
natural history and risk factors associated 
with LUTS/BPH, information on physician-
practice patterns, the longitudinal 
relationship between LUTS, sexual function 
and quality of life, and patient outcomes is 
limited.
A disease registry provides a systematic 
and inclusive database of information 
on representative individuals with an 
identified category of disease from a 
defined population [8]. A disease registry 
offers various differences in design and 
capability from a clinical trial. Unlike a clinical 
trial, which evaluates efficacy, a disease 
registry evaluates the effectiveness of 
management practices. Although a clinical 
trial provides data that can be useful for 
evidence-based recommendations on patient 
care, a disease registry provides data on 
patient care in actual practice settings, and 
changes in management over time. Whereas a 
clinical trial is conducted in a controlled 
setting, treatment is pre-specified by protocol, 
patients are evaluated at specified intervals, 
and enrolment is restricted by pre-specified 
inclusion and exclusion criteria, a disease 
registry documents actual care, treatments 
are not specified by protocol, patient visits are 
not controlled, and enrolment criteria are 
usually broad. A disease registry also 
offers an opportunity to assess whether 
physicians adhere to the practice guidelines 
recommended by speciality groups, societies 
and governmental organizations. Accordingly, 
data from a disease registry complement data 
from randomized clinical trials by providing 
clinicians, researchers, and policy makers with 
information on the actual implementation 
and effect of BPH treatments in a broader 
population of patients.
The BPH Registry and Patient Survey (BRPS), 
an ongoing, prospective, observational 
multicentre, disease registry, is collecting 
clinical and outcome data on men with 
LUTS/BPH who are managed by a 
geographically diverse group of urologists 
and primary-care physicians in the USA. This 
report describes the design and methods of 
the BRPS and baseline demographic and 





The BRPS Steering Committee (see 
Acknowledgements), which comprises 
urologists, primary-care physicians, health 
services researchers, psychologists, and a 
biostatistician, was created to conceptualize 
the design and to oversee all scientific 
decisions on the conduct of the BRPS. A 
clinical research organization (i3 Research, 
Basking Ridge, NJ, USA) was contracted for 
data collection, database management and 
reporting. The BRPS is being conducted in 
accordance with Good Clinical Practice 
guidelines. Each principal investigator/
physician was required to submit registry 
documents and obtain Institutional Review 
Board approval before performing any 
registry-related procedures. The BRPS is 
funded by Sanofi-Aventis.
The overall objectives of the BRPS are: (i) 
to examine physician management practices 
and patient outcomes, including symptom 
amelioration and disease progression; (ii) 
to gain a better understanding of the 
relationship between LUTS and sexual 
dysfunction in ageing men; (iii) to 
further validate the Men’s Sexual Health 
Questionnaire (MSHQ) [9]; and (iv) to provide 
a benchmark for clinical outcomes against 
regional and national results. The registry was 









men. Based on long-term data on overall 
clinical disease progression and the failure of 
medical therapy from the Medical Therapy of 
Prostate Symptoms trial [10], participants are 





Physician management practices and patient 
characteristics and outcomes in the registry 
will be examined using descriptive statistics 
and various statistical models that address 
the relationship between a response/outcome 
and various exploratory variables. Clinical and 
quality-of-life measures will be assessed at 
baseline and at the follow-up, and expressed 
as the mean change from baseline. Analysis of 
covariance and regression models will be 
developed and the statistical significance of 
prognostic variables will be determined at the 
0.05 level. Correlations between various 
clinical variables will be determined using 
Pearson product-moment and Spearman 
rank-order correlation. Demographic data and 
safety data will be summarized using 
descriptive statistics.
A geographically diverse group of USA 
urologists and primary-care physicians 
enrolled eligible men with LUTS/BPH (Fig. 1). 
We sought a ratio of urologists to primary-




2 : 1; a maximum of 50 
men could be enrolled at each investigational 
site. The primary inclusion criterion was a 
diagnosis of LUTS/BPH that was untreated 
(newly diagnosed or managed with watchful 
waiting, WW, or botanical products) or 












inhibitor (5ARI), a combination of an AB and a 
5ARI, or anticholinergics. ‘Recently treated’ 










3 months before enrolment. 
Patients were excluded if they had 
concomitant LUT disease or carcinoma, a 
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history of prostatic surgery, including 
minimally invasive procedures, isolated 
bladder neck disease or urethral stenosis/
strictures, gross haematuria, current acute 
urinary retention, neurological disease or 
other condition that has a direct effect on 
urinary function, acute renal disease, or active 
liver disease, were using LHRH analogues or 
antiandrogens, or were currently enrolled in a 
clinical or research study. Patients follow the 
management plan developed in collaboration 
with their physicians throughout the registry, 
with no treatments or patient clinic/office 
visits specified by protocol.
At enrolment (baseline visit), after explaining 
the protocol, obtaining informed consent, and 
providing the Health Insurance Portability and 
Accountability Act statement to enrolees, site 
investigators collected three types of data: 
(i) pre-enrolment data on current BPH 
management; (ii) baseline demographic and 
clinical information, overall assessments, and 
self-reported data on LUTS and LUTS bother, 
sexual function, and health-related quality of 
life using physician- and patient-completed 
forms and questionnaires; and (iii) data after 
enrolment on BPH management (Table 1) 
[9,11–14]. Follow-up visits are scheduled 
according to each physician’s usual 
procedure. Once enrolled, patients could 
continue their pre-enrolment therapy or 
switch to another medical therapy or WW, 
according to decisions made by the physician 
and/or patient. We sought a sample in which 
about a third of men were managed with WW, 
about a third were presently/recently treated, 
and about a third were switched from WW to 
treatment.
At the baseline visit, each physician 
completed: (i) a Physical Examination and 
Treatment Form on each patient’s LUTS/BPH 
history and any treatment prescribed or 
continued; and (ii) a Clinical History Form on 
comorbidities, concomitant medications, and 
any reported adverse events (unsolicited 
common complaints). Each patient 
completed: (i) a Baseline Form on 
sociodemographic information; (ii) self-
administered questionnaires, including the 





7 indicating mild, of 8–19 





severe LUTS) and the IPSS Bother Question 




2 indicating mild, 





severe bother); the four-item BPH Impact 
Index [12] (total score 0–12, with higher 
scores indicating a greater negative impact 
of BPH symptoms); the MSHQ [9], which 
includes a three-item erection domain (total 
score 1–15, with lower scores indicating 
decreased function), an erection bother 
question (score range of 0–5, with higher 
scores indicating greater bother), a seven-
item ejaculation domain (total score 1–35, 
with lower scores indicating decreased 
function), an ejaculation bother question 
(score 0–5, with higher scores indicating 
greater bother), and a six-item satisfaction 
domain (total score 6–30, with lower scores 
indicating decreased satisfaction); the five-
item Sexual Health Inventory for Men [13] 
(SHIM or International Index of Erectile 
Function-5), with a total score of 5–25, 




21 indicating ED; the 
12-Item Short Form Health Survey (SF-12) 
[14], with a Mental Component Score (MCS; 
score 0–100, with higher scores indicating 
better quality of life) and a Physical 
Component Score (PCS; score 0–100, with 
higher scores indicating better quality of life) 
that are standardized to a general USA 




 10; and a Global 
Assessment Form (GAF) on the bother 
associated with urination problems and on 








Follow-up visitsBefore enrolment Baseline After enrolment
Physician-completed
Physical Examination and X X
Treatment Form
Clinical History Form X X X




IPSS/IPSS Bother [11] X X
BPH Impact Index [12] X X
MSHQ [9] X X
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At each follow-up visit, each physician 
completes: (i) a Physical Examination and 
Treatment Form on LUTS/BPH history and any 
treatment prescribed or continued or any 
surgery since the last visit; (ii) a Clinical 
History Form on comorbid conditions, 
concomitant medications, and any patient-
reported common complaints; and (iii) a 
Serious Adverse Event Form to describe any 
medical occurrence that results in death, 
is life-threatening, requires inpatient 
hospitalization or prolongation of existing 
hospitalization, results in significant 
disability/incapacity, is a congenital anomaly, 
or other medically important event. At each 
follow-up visit, each patient completes: (i) a 
Follow-up Form on health insurance, any 
discontinuations of medication, out-of-
pocket expenses for treatment of urinary 
symptoms, and any visits to other doctors or 
the emergency room for urinary symptoms; 
and (ii) the self-administered IPSS, BPH 
Impact Index, MSHQ, SHIM, and GAF. If a 
patient does not have an in-office follow-up 




 1 months of the last visit, the 
follow-up forms and questionnaires are 
mailed to the patient with instructions for 
their completion. A Final Status Form is 
completed by the physician when a patient 
completes (i.e. the investigator is satisfied 
that patient fulfils all registry requirements) 
or discontinues from the BPRS. In cases of 
discontinuation, the physician records the 
reason for discontinuation (e.g. did not meet 
inclusion/exclusion criteria, withdrawal of 
consent, adverse event, lost to follow-up, 
patient referred to another physician, new 
diagnosis of bladder or prostate cancer, 
patient enrolled in clinical or research study, 





The first patient was enrolled on 23 January 
2004 and the last on 25 February 2005. 
Enrolment in the BPRS was closed on 28 
February 2005. At the time of the present 
baseline analysis (6 June 2005), data were 
available for 6909 men who were enrolled at 
402 sites (Table 2), with 4537 (66%) men seen 
by urologists and 2372 (34%) seen by 
primary-care physicians. As of the present 
analysis, 634 (9%) of the men had 
discontinued their participation in the 
registry, with withdrawal of consent (340 











economic characteristics of 
enrolled men at baseline
 
Variable (N)
N (%) patients or
baseline value
Patients enrolled 6909 (100)
Patients discontinued 634 (9)
Reason for discontinuation
Did not meet inclusion/exclusion criteria 46 (1)
Withdrawal of consent 340 (5)










Lost to follow-up 81 (1)










New diagnosis prostate/bladder cancer 50 (1)

















































Married/living with significant other 5165 (80)





 High school diploma 578 (9)
High school diploma/equivalent 1669 (26)




 College degree 2573 (40)




15 000 537 (9)
15 000–29 999 1033 (17)
30 000–49 999 1416 (23)
50 000–74 999 1330 (22)




150 000 382 (6)





Drug coverage plan with co-pay 592 (12)
Other 327 (6)






*As of 6 June 2005; †Health 
insurance categories are 
not mutually exclusive.
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The mean (range) age of the enrolled men at 
baseline was 66.0 (30–94) years and most 
(83%) were white (Table 2). Of 3236 men with 













80% of the men were 
married or living with a partner, 64% had at 
least some education beyond a high school 
diploma, and 74% had household incomes of 
at least US$ 30 000.
At baseline, the mean time since the diagnosis 
of BPH was 4 (0–49) years, whereas the mean 
time since LUTS were first experienced was 
5 (0–49) years; Table 3). Overall, 2065 (33%) 
of the 6184 men who completed the IPSS 




7), 3218 (52%) had 





20). Of 5137 men who had a 
DRE, 2025 (39%) had a moderately or 
significantly enlarged prostate. Total PSA 
levels had a wide range of values (0.1–
117.9 ng/mL), with a median of 1.9 ng/mL. 
In all, 6284 men (94%) had at least one 
comorbid condition at the baseline visit. 
The most common comorbidities were 
hypertension (53%), high cholesterol (45%) 
and sexual dysfunction (36%) (Table 3).
Before enrolment, 6653 (96%) of the 6909 
men had data on their BPH management 
strategy, whereas 6667 (96%) had data on 
their strategy after enrolment. Before 
enrolment, 3258 (49%) of men with available 
data were managed with WW, 21% with 
selective ABs, 11% with non-selective ABs, 
11% with ABs and 5ARIs, 6% with 5ARIs and 
2% with anticholinergics. At the end of the 
enrolment visit, 42% of the men were 
managed with WW, and the respective 
percentages were 26%, 11%, 12%, 7% and 
2%. Thus, the percentage of men who 
switched from WW to medical treatment at 
the baseline visit was only 7%, which was less 
than the a priori estimate of 33%. The 
percentage of men receiving a uroselective AB 
(alfuzosin or tamsulosin) increased from 21% 
before enrolment to 26% after, whereas the 
percentage of men receiving each of the other 
BPH management options was essentially 
unchanged.
The mean SHIM score at baseline was 16.5 
(Table 4), indicating that on average the men 
had mild-to-moderate ED. The mean MSHQ 
erection domain score of 8.4 also suggested a 
mild-to-moderate degree of ED. Likewise, the 
mean MSHQ bother score indicated that the 
men were ‘a little bit’ to ‘moderately’ bothered 
by their ED. ED was also reported as a 
common complaint by 1312 (50%) of 2643 
men with a complaint at the enrolment visit. 
The mean MSHQ ejaculation domain score 
was 24.1, and the mean MSHQ bother score 
was 4.0. Of 2643 men who reported a 
complaint at the baseline visit, 104 (4%) 
reported abnormal ejaculation and 158 (6%) 
reported reduced ejaculate volume. About 
half of men with a complaint of ED and two-
thirds of those with a complaint of 
ejaculatory dysfunction were receiving 
medical therapy for their LUTS/BPH.
The mean PCS and MCS of the SF-12 (Table 4) 
suggested that the men had a similar quality 
of life at baseline as a general USA population. 
Of 6318 men who completed the GAF before 
enrolment, 33% reported that trouble with 
urination was ‘not at all bothersome’, 39% 
reported that it ‘bothers me a little’, and 28% 
indicated that it bothered them ‘some’ or 
‘a lot’ during the past month. More men 
reported being satisfied with their sex lives 




The clinical characteristics of the enrolled men at baseline
 






time since first LUTS, years 4595 5 (5)
time since BPH diagnosis, years 5888 4 (5)
maximum urinary flow rate, mL/s 1045 12 (7)
Prostate size (DRE), n (%) 5137
normal 864 (17)
slightly enlarged 2248 (44)
moderately enlarged 1695 (33)
significantly enlarged 330 (6)
total PSA, ng/mL 5420 2.9 (4.4)
total IPSS (range 0–35) 6184 11.6 (7.1)
IPSS bother score (range 0–6) 6415 2.5 (1.5)
BPH Impact Index (range 0–12) 6450 2.8 (2.8)
Comorbidities, N (%)* 6284
allergies/cold/flu/congestion 1070 (15)
arthritis 1357 (20)
depression/anxiety/sleep disorder 1117 (16)
diabetes 1196 (17)
digestive tract disorder 1427 (21)
general pain/inflammation 777 (11)
heart disease/heart failure 1227 (18)
high cholesterol 3094 (45)
hypertension 3658 (53)
erectile or other sexual dysfunction 2511 (36)
 




Sexual function and quality 
of life of enrolled men at 
baseline
 






Erection domain (1–15) 5786 8.4 (4.4)
Erection bother (0–5) 5785 3.6 (1.3)
Ejaculation domain (1–35) 5795 24.1 (7.7)
Ejaculation bother (0–5) 5534 4.0 (1.2)
Satisfaction domain (6–30) 5382 22.5 (5.9)
SHIM [13] (5–25) 5619 16.5 (6.6)
SF-12 [14] 3726
MCS (0–100) 52.2 (9.2)
PCS (0–100) 47.4 (9.7)
 
For all variables, a higher 
score indicates a better 
outcome.
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‘mostly satisfied’ with their sex lives, whereas 










50 years, white, 
married and well-educated. Their common 
comorbidities include hypertension, high 
cholesterol and sexual dysfunction, with 
prevalence rates that are comparable to those 





[4,15]. Men enrolled in the registry had a 
broad range of LUTS severity (33% mild, 52% 
moderate and 15% severe LUTS), which 
contrasts with most BPH clinical trials in 
which enrolment criteria pre-specify that men 
have moderate-to-severe LUTS. Thus, the men 
enrolled in the BPRS represent a USA 
population presenting with LUTS/BPH to 
urologists or primary-care physicians in 
everyday clinical practice, and can be 
longitudinally followed for their disease 
management and outcomes. Observation of 
this BPRS population might provide better 
insights on symptom progression, as a greater 
proportion of these men have mild LUTS than 
in standard BPH clinical trials. Only two other 
BPH-related registries, which monitor results 
of specific procedures in a few patients, the 
European Association of Urology Real Life 
Data Registry with Transurethral Needle 
Ablation Therapy [16] and the international 
registry for an interstitial laser device [17], 
were reported previously.
As there are now more older men because 
of the ageing of the population and 
increased life-expectancy, appropriate 
management and use of resources for 
chronic diseases, including LUTS/BPH, 
have become major challenges for the 
healthcare system. This, together with a 
change from primarily surgical procedures 
to medical therapy as the first-line 
management approach for LUTS/BPH, and 
from predominantly urologists to primary-
care physicians as the initial healthcare 
providers managing men with LUTS/BPH, has 
created a need for a better understanding 
of current physician practice patterns and 
patient outcomes.
The longitudinal BPRS was initiated to provide 
a comprehensive database of information 
on physician practice patterns and health 
outcomes of men with BPH who are 
initially managed conservatively with either 
WW or medical therapy. Although evidence-
based treatment guidelines exist on the 
management of LUTS/BPH [7], data are 
needed on any differences between these 
recommendations and actual treatment 
decisions in clinical practice settings. The 
role of possible confounding variables, 
including demographics, socio-economics, 
comorbidities, and physician speciality, also 
needs to be explored. The database from 
the BPRS should complement data derived 
from clinical trials and provide a different 
and unique real-world perspective on 
management practices and outcomes for 
LUTS/BPH.
Limitations of the BPRS include a selection 
bias of physicians, that might have occurred 
because physicians enrolling men in the 
registry were not randomly selected but 
rather chose to participate. Selection bias is 
also a possibility for the men enrolled in the 
registry, but the prevalence rates of various 
comorbidities (e.g. hypertension, high 
cholesterol) in the enrolled men suggests that 
they are generally representative of an ageing 
USA male population [4,15]. Data from 
registries can also be limited by having too 
few patients receiving certain interventions or 
by patients with mild disease who do not 
warrant medical therapy.
In conclusion, the BPRS will provide a 
comprehensive database of information 
for assessing risk factors for LUTS/BPH, 
current physician-practice patterns in the 
management of LUTS/BPH, and health 
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